FTC vs CVS Caremark: Systemic price‑fixing, PBM power, and global insulin inequities revealed
Original framing: “STAT+: FTC settles lawsuit with CVS Caremark over charges it manipulated insulin prices, impeded access” — STAT News
Scientific evidence confirms that insulin demand is inelastic, allowing manufacturers and PBMs to sustain high prices without reducing consumption. Pharmacoeconomic modeling demonstrates that transparent cost accounting could reduce prices by up to 30 % without compromising supply chain stability.
The FTC settlement spotlights a single corporate infraction while the deeper problem lies in a market architecture that privileges PBM profit over patient health, a pattern reinforced by historical patent strategies and regulatory capture.
Indigenous and traditional health practices, together with cross‑cultural procurement models, demonstrate viable alternatives that can reduce reliance on expensive insulin. Scientific and future‑modelling evidence shows that transparent pricing and antitrust enforcement can dramatically lower costs, while artistic‑spiritual narratives and trickster analyses reveal the moral absurdities of current policies. By amplifying marginalised patient voices and integrating community‑owned purchasing, policymakers can dismantle the entrenched power structures that sustain insulin inequity.